“We treated successfully many hundreds of the high risk

New Post Public Reply Private Reply Replies (2) Message Board
Rubraquercus Rubraquercus #74390
961
“We treated successfully many hundreds of the high risk and symptomatic patients,” Dr. Fareed testified, noting that he uses a triple HCQ cocktail: HCQ (3200 mg over 5 days), ivermectin, azithromycin or doxycycline and zinc aimed at disrupting viral replication.

Vitamins C and D as well as Quercetin, anti-coagulants and corticosteroids such as dexamethasone and prednisone further “reduce the risk of escalation to cytokine storm and blood-clotting,” he said.

“The multi-drug cocktail is best given early within the first 5 to 7 days while the patient is in the flu stage. I use it especially in high risk individuals, anyone over 60 or with co-morbidities, and anyone with moderate to severe flu symptoms,” Dr. Fareed explained.

“I used this regimen to successfully treat 31 elderly nursing home residents in an outbreak in June. 29 recovered fully,” he added.

“The science tells us that early treatment would be an effective strategy to use on a national level,” Farred said. “This realization motivated me and a few of my colleagues to write a letter to the President, a letter to my congressman, a letter to California health department, an Open Letter to Dr. Fauci, and a National Plan for Covid-19.

“As we describe in the National Plan, this approach would be the solution to the pandemic; protect the vulnerable, and if high risk individuals get sick, there is a solution for them as well—early treatment with the antiviral cocktail.”

It bears noting that HCQ has not been included in the NIH’s “upgrades” on Covid treatments although it continues to be re-purposed as a frontline Covid treatment in many parts of the world.

Despite voluminous evidence of its safety and efficacy by leading experts, including FLCCC physicians at the May and November Senate hearings, government health agencies have consistently blocked the drug’s release from national stockpiles.

Delaying Treatment Can Be Disastrous

“This is a very insidious disease and as we’ve seen, it can progress to deadly levels with no explanation,” Dr. Peter McCullough of Baylor University Medical Center Hospital in Dallas, stressed at the Senate hearing. “The idea of not treating it until a patient gets to the hospital does not make sense.”

“Unlike the flu or viruses that caused previous pandemics, Covid-19 can lead to three distinct, lethal outcomes: viral damage to organs, cytokine storm, and micro-thrombosis (blood clots). The mortality curve can reach 30 days [after infection],” Dr. McCullough noted.

“Patients wait in fear at home after testing positive, logically thinking they would face a terrifying hospitalization, isolation, and at worse–death. But delayed treatment for many can be disastrous. Early home treatment is the answer. The hospital should only be a safety net for survival. It should not be the first place of treatment.”

“The United States would be wise to follow what India and Brazil have done and make available at-home Covid-19 treatment kits containing dosages of ivermectin, HCQ and key vitamin supplements,” Dr. McCullough urged. “Why should someone getting infected in the United States have a greater chance of dying from the disease, than a citizen of poorer countries who has access to early treatment?”

McCullough urged the Senate committee “to ask all responsible government agencies to prioritize an early treatment initiative. Competent physicians should be supported by all stakeholders in their efforts to provide patients with compassionate care, reduce the spread of infection, and avoid hospitalization and death,” he said.

“I believe this is the only viable strategy to avoid catastrophic loss of life before natural immunity and vaccination can bring this crisis to a close,” he concluded.

‘The Virus is Easy to Kill’

Renowned gastroenterologist Dr. Thomas Borody, medical director of Australia’s Center for Digestive Disease, was one of the first experts calling for ivermectin to be used for Covid treatment as early as last August.

Borody who is credited with developing a triple therapy that eradicates peptic ulcers once thought to be incurable, has joined forces with California researcher Dr. Sabine Hazan, founder of Ventura Clinical Trials, to create a protocol for Covid treatment.

“Studies on ivermectin show amazing success–clear and statistically significant benefits for pre-exposure and post-exposure prophylaxis, as well as effectively reducing mortality in early and late disease phases,” Barody said in a televised interview on Sky News.

“The virus is surprisingly easy to kill,” he said.

Borody said an ivermectin tablet could cost as little as $2, which is likely why drug makers haven’t promoted the drug’s usage. He also suggested that having a relatively easy way to wipe out the disease would drastically reduce hospitalizations which in turn would sharply cut industry profits. Not everyone is going to be happy about that, which is perhaps why the establishment continues to ignore outpatient Covid remedies.

Doctors can’t get government health agencies to even look at the medical data, Dr. Borody said, noting that his effort to alert his own government to the “powerful activity of ivermectin against the virus on the intercellular level” was met with silence.

“Neither the United States or Australia have a curative program for Covid-19. It’s all about lockdowns and vaccines,” he said. The vaccine has benefits but as its proponents admit, “it does not cure the disease or prevent its transmission. Ivermectin does both.”

Some have noted that the vaccine was issued with an Emergency Use Authorization (EUA), which falls short of full FDA approval as its long-term safety has not yet been assured. According to the law, the EUA remains valid only as long as no other safe, effective medical alternative exists.

Could Ivermectin’s potential success in eradicating Covid be seen as reducing the need for a vaccine, Dr. Borody was asked in an interview. He dismissed this notion, saying both options are vital. “The guiding principle is to use all available means to save lives now. To end the pandemic we must treat and vaccinate, treat and vaccinate.”
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 71

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 92

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
STVN's GLP-1 Fumble Sparks Shareholder Scrutiny

Updated Category News Views 35

The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading
ROBOTWORLD 2026: AI Reshapes Industrial Horizons

Updated Category News Views 48

A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 94

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 0

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 101

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Compass Faces Securities Fraud Suit: Deadline Looms

Updated Category News Views 45

Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...

Continue Reading
s of Cautious Optimism - Continue Reading" aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism"> Continue Reading